Bharat Biotech International Limited (BBIL) has introduced a novel single-strain Oral Cholera Vaccine (OCV) named HILLCHOL® in Hyderabad.

This vaccine was developed in collaboration with Hilleman Laboratories and is supported by funding from Merck, USA, and the Wellcome Trust, UK.

BBIL’s Executive Director, Dr. Krishna Ella, emphasized that HILLCHOL® is a testament to successful partnerships that drive public health advancements.

He also mentioned that their new production facilities in Hyderabad and Bhubaneswar will significantly boost the manufacturing and distribution of the Oral Cholera Vaccine, aiding in the global fight against cholera.